Module may be used by facilities other than hospitals, including outpatient dialysis centers. A report of data from this module for outpatient dialysis centers was published separately. 8 NHSN facilities contributing HAI surveillance data to this report did so voluntarily in response to state mandatory reporting requirements or in compliance with the Centers for Medicare and Medicaid Services' (CMS) Hospital Inpatient Quality Reporting Program. The CDC aggregated these data into a single national database for 2011, consistent with the stated purposes of NHSN, which were as follows:
Collect data from a sample of health care facilities in the United States to permit valid estimation of the magnitude of adverse events among patients and health care personnel;
collect data from a sample of health care facilities in the United States to permit valid estimation of the adherence to practices known to be associated with prevention of these adverse events; analyze and report collected data to permit recognition of trends; provide facilities with risk-adjusted metrics that can be used for interfacility comparisons and local quality improvement activities; assist facilities in developing surveillance and analysis methods that permit timely recognition of patient and health care worker safety problems and prompt intervention with appropriate measures; conduct collaborative research studies with NHSN member facilities (eg, describe the epidemiology of emerging HAI and pathogens, assess the importance of potential risk factors, further characterize HAI pathogens and their mechanisms of resistance, and evaluate alternative surveillance and prevention strategies); comply with legal requirementsdincluding but not limited to state or federal laws, regulations, or other requirementsdfor mandatory reporting of health care facility-specific adverse event, prevention practice adherence, and other public health data; enable health care facilities to report HAI and prevention practice adherence data via NHSN to the US CMS in fulfillment of CMS's quality measurement reporting requirements for those data; provide state departments of health with information that identifies the health care facilities in their state that participate in NHSN; and provide to state agencies, at their request, facility-specific NHSN patient safety component and health care personnel safety component adverse event and prevention practice adherence data for surveillance, prevention, or mandatory public reporting.
Patient-and facility-specific data reported to CDC are kept confidential in accordance with sections 304, 306, and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m [d] ).
METHODS

Data collection methods
For reporting to the DA Module, health care facility personnel responsible for infection prevention and patient safety may choose, with consideration of state mandates, federal reporting programs, and prevention initiatives, to collect data on central line-associated primary bloodstream infections (CLABSI), ventilator-associated pneumonias (VAP), or urinary catheter-associated urinary tract infections (CAUTI) that occur in patients staying in a patient care location such as a critical or intensive care unit (ICU), specialty care area, or inpatient ward. In NHSN, locations are further stratified according to patient population: adults, children, or neonates (in tables, pediatric and neonatal locations are so noted). In neonatal intensive care unit (NICU) locations (level III or level II/III), infection preventionists (IPs) collect data on central line-associated and umbilical catheter-associated BSI or VAP that occur in patients in each of 5 birth-weight categories ( 750 g, 751-1,000 g, 1,001-1,500 g, 1,501-2,500 g, and >2,500 g); data on CAUTI are not collected as part of the NHSN protocols in any NICU location. Corresponding location-specific denominator data consisting of patient-days and specific device-days are also collected by IPs or other trained personnel.
In non-NICU locations, the device-days consist of the total number of central line-days, urinary catheter-days, or ventilatordays. For specialty care areas, such as hematology/oncology and hematopoietic stem cell transplant locations, central line days are split into those with only a permanent central line versus those with temporary central lines (with or without a permanent central line). In NICU locations, the device-days consist of the total number of central line-days and umbilical catheter-days or ventilator-days for each birth-weight category.
Data analysis methods
Compared with the previous report, 5 new locationsdpediatric surgical critical care, long-term care rehabilitation unit, long-term acute care critical care, long-term acute care ward, and inpatient rehabilitation facilitydhad sufficient data to be included in this report. 1 Locations were further stratified by unit bed size and/or major teaching status to determine whether pooled mean rates, medians, and empirical distributions significantly differed between 2 groups for all DA infections; if differences were present, the strata were retained for reporting. Comparisons of pooled mean rates were performed using Poisson regression. These comparisons could be influenced by potential outlier rates from locations with disproportionately large denominators. Therefore, greater weight was given to the results of nonparametric tests comparing the medians for location shift and empirical distributions for assessing differences across the range of reported rates. These nonparametric comparisons by definition require no validity assumptions and provide test results that are not subject to the potential weighting influence of high or low rates with large denominators. Comparisons of the median and percentile distribution were made if there were at least 50 locations contributing to one or more strata and at least 20 locations contributing to the percentile distribution in both strata.
Existing strata were retained for adult combined medical/ surgical ICUs, medical ICUs, and surgical ICUs. The data for adult combined medical/surgical ICUs were split by hospital type and unit bed size, resulting in 3 groups: "major teaching," "all others" with unit bed size 15 beds, and "all others" with unit bed size >15. The data for adult medical ICUs and adult surgical ICUs were split into 2 groups by teaching status. Facilities self-identified teaching status through an annual facility survey. Major teaching status was defined as a hospital that is an important part of the medical school teaching program in which the majority of medical students rotate through multiple clinical services. Adult bone marrow transplant and adult hematology/oncology locations were also evaluated to assess importance of status as an oncology hospital, but differences were not significant, and no new strata were retained.
Device utilization (DU) was calculated as a ratio of device-days to patient-days for each location type. As such, the DU of a location is one measure of the use of invasive devices and constitutes an extrinsic risk factor for HAI.
9 DU may also serve as a marker for severity of illness of patients (ie, more severely ill patients are more likely to require an invasive device), which is another reflection of the intrinsic susceptibility to infection. Data from at least 5 different reporting units of a given location type were used to determine pooled mean DA infection rates and DU ratios. Percentile distributions were determined if there were data from at least 20 different locations, excluding rates or DU ratios for locations that did not report at least 50 device-days or patient-days. Because of these requirements, the number of locations contributing data may vary among the tables.
RESULTS
In 2011, 3,854 hospitals reported at least 1 month of DA denominator data for some patient cohorts under surveillance. These 3,854 hospitals were located in 53 states, territories, and the District of Columbia and were predominantly general acute care y The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, !50 device days for rate distributions, !50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. (Table 2) . Additionally, 60% of the hospitals included in this report are located in states with a mandate for reporting at least 1 type of DA infection to NHSN. Where data volume was sufficient for this report, we tabulated DA infection rates and DU ratios for January through December 2011 (Tables 3-10) . Data on the specific criteria used to report DA infections are provided in Tables 11 to 18.  Tables 3 to 6 update and augment previously published DA rates and DU ratios by type of non-NICU locations. 1 Beginning in 2012, long-term acute care (LTAC) units were recategorized by acuity level into critical care or ward designations; therefore, to align with current data reporting methods in this location type, LTAC data in this report have been categorized in the same manner. Additionally, data from inpatient rehabilitation facilities, as defined by the CMS, have been reported separately from non-inpatient rehabilitation facilities rehabilitation wards within acute care hospitals. Tables 7 to 10 update and augment the previously published DA rates and DU ratios by birth-weight category for NICU locations. 1 Beginning in January 2012, CLABSI data in NICU locations are no longer collected according to central line type (ie, central line and umbilical catheter); to align with the current reporting of these data, CLABSI rates and DU ratios for NICUs are not stratified by line type in this report. Tables 11 to 18 provide data on select attributes of the DA infections for each location. For example, Tables 11, 12, 15, and 16 show the frequency and percent distribution of the specific sites of CLABSI and the criteria used for identifying these infections. Note that, for these tables, criteria 2 and 3 have been combined.
DISCUSSION
This report summarizes the HAI data reported to the DA module of NHSN during 2011. The data in this report continue to be restricted to a single year for several reasons. First, NHSN saw continued growth in participation because of state mandates and federal reporting programs, and, because of this, there were sufficient data reported in 2011 to support the analysis of a single year of data (eg, considerable data contributing to the pooled means, most location types with >20 locations reporting), thus obviating the need to combine data with previous years. Second, analyzing 1 year of data removes the need to assess the influence of any large increase of new reporters in a single year of a multiyear summary measure. Finally, by restricting data to a single year, changes in HAI rates are more apparent and can highlight continued prevention efforts in different patient care areas. This strategy also fulfills the need for more timely publication of comparative rates.
The characteristics of hospitals reporting to NHSN are similar to those seen in the last published report, although this report demonstrates a slight increase in contribution from smaller hospitals. 1 Based on the number of facilities reporting, overall contribution to the DA module increased by 56% from the last report. 1 This increase in reporting is largely attributed to hospitals' participation in the CMS Hospital Inpatient Quality Reporting Program, which requires participants to use NHSN as the tool to report CLABSI data from all adult, pediatric, and neonatal ICUs beginning in January 2011. Whereas much of this growth impacted the volume of CLABSI reporting in ICUs, there is an indication of increased participation in non-ICU locations for CLABSI reporting, as well as reporting for other HAIs in this module. Extensive analyses of the impact of hospital type on all DA infection rates were performed for select ICU locations. Hospital type continues to be a significant factor for all 3 DA infection rates and percentile distributions in medical ICUs and surgical ICUs. Additionally, hospital type and bed size both continue to be significant factors in DA infection rates for medical/surgical ICUs. Note that, whereas the CLABSI rates between unit bed size strata in medical/surgical "all other" ICUs are equal (Table 3) , the percentile distributions were shown to be significantly different as a result of nonparametric statistical tests. Therefore, this stratification by unit bed size in "all other" medical/surgical ICUs was retained. Adult bone marrow transplant and adult hematology/oncology locations were not further stratified by hospital type (ie, oncology hospital vs all other acute care hospitals) as the results of the statistical tests indicated that the differences in the strata were not statistically significant. Beginning in 2013, oncology hospitals will be provided with 14 oncology-specific CDC locations with which to identify for DA infection surveillance. As the volume of these data becomes sufficient, future analyses will continue to assess any potential differences in this specialized population. Tables 11 to 18 were included to aid the reader in interpreting the DA infection rates data. One important use of these data is to better understand the distribution of DA infections by type of reporting criterion nationally. For example, approximately 82% of the CLABSIs from adult and pediatric ICU and inpatient wards were identified using the least subjective criterion, 1 which attributes the CLABSI to a recognized pathogen; however, for NICUs, approximately two-thirds used this criterion, resulting in a greater percentage of CLABSIs in this population that were identified with common commensals. Similarly, the specific type of VAP most frequently reported, regardless of location, was the clinical criterion (PNU1), which relies on the somewhat subjective interpretations of clinical findings. As more and diverse types of facilities participate in NHSN either voluntarily or by mandate, the need for careful scrutiny of the data increases. We will continue to assess how the changing composition of facilities and the changing proportion of data contributed by various types of facilities impact the rates and their distributions so that the best possible risk-adjusted comparative data may be provided in future reports.
To improve the reliability of data reported to NHSN, several protocol changes are set to occur in January 2013. The majority of these changes are with respect to timing and implementation of 2-day rules to clarify infections that are health care associated, association of device use to HAI, and attribution of HAI to an inpatient location after transfer or to a hospital after discharge. In addition, NHSN will add criteria for mucosal barrier injury laboratory-confirmed BSI. Finally, the VAP definition will no longer apply to adult patients (ie, !18 years of age), and this definition will be replaced by ventilator-associated events. 10 We will carefully assess the potential impact of these changes on HAI incidence as these data are reported.
For those who do not report to NHSN but would like to use these data for comparison, the information must first be collected from your hospital in accordance with the methods described for The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, !50 device-days for rate distributions, !50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, !50 device-days for rate distributions, !50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated.
z Includes freestanding long-term acute care hospitals and long-term acute care locations within the general acute care hospital setting.
Table 9
Pooled means and key percentiles of the distribution of ventilator-associated PNEU rates and ventilator utilization ratios for level III NICUs, DA module, 2011
Ventilator-associated PNEU rate* Percentile
Birth-weight category No. of locations y The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, !50 device-days for rate distributions, !50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. y The number in parentheses is the number of locations meeting minimum requirements for percentile distributions (ie, !50 device-days for rate distributions, !50 patient days for device utilization ratios) if less than total number of locations. If this number is <20, percentile distributions are not calculated. NHSN. [5] [6] [7] Refer to Appendices 1 and 2 for further instructions.
Appendix 1 discusses the calculation of infection rates and DU ratios for the DA Module. Appendix 2 gives a step-by-step method for interpretation of percentiles of infection rates or DU ratios. Although a high rate or ratio (>90th percentile) does not necessarily define a problem, it does suggest an area for further investigation. Similarly, a low rate or ratio (<10th percentile) may be the result of inadequate infection detection. Facilities should use the data in this report and their own data to guide local prevention strategies and other quality improvement efforts to reduce the occurrence of infections as much as possible. The data presented in this report can be used to prioritize prevention efforts in those patient care areas that are shown to have the highest incidence of DA infections and/or high device utilization. Facilities may also wish to set targets based on the percentile distributions provided in this report in an effort to strive for lower rates and greater prevention suc65cess. Calculation of device-associated infection rate
Step 1: Decide upon the time period for your analysis. It may be a month, a quarter, 6 months, a year, or some other period.
Step 2: Select the patient population for analysis, eg, the type of location or a birth-weight category in a NICU.
Step 3: Select the infections to be included in the numerator. They must be site specific and must have occurred in the selected patient population. Their date of onset must be during the selected time period.
Step 4: Determine the number of device-days, which is used as the denominator of the rate. Device-days are the total number of days of exposure to the device (central line, umbilical catheter, ventilator, or urinary catheter) by all of the patients in the selected population during the selected time period.
Example: Five patients on the first day of the month had 1 or more central lines in place; 5 on day 2; 2 on day 3; 5 on day 4; 3 on day 5; 4 on day 6; and 4 on day 7. Adding the number of patients with central lines on days 1 through 7, we would have 5 þ 5 þ 2 þ 5 þ 3 þ 4 þ 4 ¼ 28 central line-days for the first week. If we continued for the entire month, the number of central line-days for the month is simply the sum of the daily counts.
Step 5: Calculate the device-associated infection rate (per 1,000 device-days) using the following formula:
Example:
Central line-associated BSI rate per 1; 000 central line-days
¼
Number of central line À associated BSI Number of central line À days Â 1; 000
Calculation of device utilization (DU) ratio steps 1, 2, 4:
Same as device-associated infection rates plus determine the number of patient-days, which is used as the denominator of the DU ratio. Patient-days are the total number of days that patients are in the location during the selected time period.
Example: Ten patients were in the unit on the first day of the month; 12 on day 2; 11 on day 3; 13 on day 4; 10 on day 5; 6 on day 6; and 10 on day 7; and so on. If we counted the patients in the unit from days 1 through 7, we would add 10 þ 12 þ 11 þ 13 þ 10 þ 6 þ 10 for a total of 72 patient-days for the first week of the month. If we continued for the entire month, the number of patient-days for the month is simply the sum of the daily counts.
Step 5: Calculate the DU ratio with the following formula:
DU Ratio ¼ Number of device À days Number of patients À days Device-associated Infection Rate ¼ Number of device À associated infections for an infection site Number of device À days Â 1; 000
With the number of device-days and patient-days from the examples above, DU ¼ 28/72 ¼ 0.39 or 39% of patient-days were also central line-days for the first week of the month.
Step 6: Examine the size of the denominator for your hospital's rate or ratio. Rates or ratios may not be good estimates of the "true" rate or ratio for your hospital if the denominator is small, ie, <50 device-days or patient-days.
Step 7: Compare your hospital's location-specific rates or ratios with those found in the tables of this report. Refer to Appendix 2 for interpretation of the percentiles of the rates/ratios.
APPENDIX 2. INTERPRETATION OF PERCENTILES OF INFECTION RATES OR DEVICE UTILIZATION RATIOS
Step 1: Evaluate the rate (ratio) you have calculated for your hospital and confirm that the variables in the rate (both numerator and denominator) are identical to variables in the rates (ratios) in the table.
Step 2: Examine the percentiles in each of the tables and look for the 50th percentile (or median). At the 50th percentile, 50% of the hospitals have lower rates (ratios) than the median, and 50% have higher rates (ratios).
Step 3: Determine if your hospital's rate (ratio) is above or below this median.
Determining whether your hospital's rate or ratio is a HIGH outlier
Step 4: If your hospital's rate or ratio is above the median, determine whether the rate (ratio) is above the 75th percentile. At the 75th percentile, 75% of the hospitals had lower rates (ratios), and 25% of the hospital had higher rates (ratios).
Step 5: If the rate (ratio) is above the 75th percentile, determine whether it is above the 90th percentile. If it is, then the rate (ratio) is an outlier, which may indicate a problem.
Determining whether your hospital's rate or ratio is a LOW outlier
Step 6: If your hospital's rate or ratio is below the median, determine whether the rate (ratio) is below the 25th percentile. At the 25th percentile, 25% of the hospitals had lower rates (ratios), and 75% of the hospitals had higher rates (ratios).
Step 7: If the rate (ratio) is below the 25th percentile, determine whether it is below the 10th percentile. If the rate is, then it is a low outlier, which may be due to underreporting of infections. If the ratio is below the 10th percentile, it is a low outlier and may be due to infrequent and/or short duration of device use.
Note: Device-associated infection rates and device utilization ratios should be examined together so that preventive measures may be appropriately targeted. For example, you find that the ventilator-associated pneumonia rate for a certain type of ICU is consistently above the 90th percentile and the ventilator utilization ratio is routinely between the 75th and 90th percentile. Because the ventilator is a significant risk factor for pneumonia, you may want to limit the duration of ventilation whenever possible (ie, decrease unnecessary use) while at the same time optimize infection prevention strategies in patients for whom ventilator use is required.
